Distribution of the c-MYC gene product in colorectal neoplasia

Histopathology

Volumn 69, Issue 2, 2016, Pages 222-229

  Baker, Ann Marie ^a   Van Noorden, Susan ^b   Rodriguez Justo, Manuel ^c   Cohen, Patrizia ^d   Wright, Nicholas A ^a   Lampert, Irvin A ^e  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d ST MARY S HOSPITAL   (United Kingdom)

^e WEST MIDDLESEX UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

c MYC; colorectal cancer; immunohistochemistry; in situ hybridization

Indexed keywords

KI 67 ANTIGEN; MESSENGER RNA;

ANTIBODY SPECIFICITY; ARTICLE; CELL SURFACE; COLORECTAL TUMOR; COMPARATIVE STUDY; CONTROLLED STUDY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; INVASIVE CARCINOMA; ONCOGENE C MYC; PRIORITY JOURNAL; PROTEIN LOCALIZATION; RECTUM ADENOMA; TRANSCRIPTION REGULATION;

EID: 84978235802     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/his.12939     Document Type: Article

References (34)

1. Eilers M, Eisenman RN. Myc's broad reach. Genes Dev. 2008; 22; 2755–2766.
2. Dang CV. MYC on the path to cancer. Cell 2012; 149; 22–35.
3. McKeown MR, Bradner JE. Therapeutic strategies to inhibit MYC. Cold Spring Harb. Perspect Med. 2014; 4; a014266.
4. Escot C, Theillet C, Lidereau R et al. Genetic alteration of the c-myc protooncogene (MYC) in human primary breast carcinomas. Proc. Natl Acad. Sci. USA 1986; 83; 4834–4838.
5. Boxer LM, Dang CV. Translocations involving c-myc and c-myc function. Oncogene 2001; 20; 5595–5610.
6. Vita M, Henriksson M. The Myc oncoprotein as a therapeutic target for human cancer. Semin. Cancer Biol. 2006; 16; 318–330.
7. Christoph F, Schmidt B, Schmitz-Drager BJ, Schulz WA. Over-expression and amplification of the c-myc gene in human urothelial carcinoma. Int. J. Cancer 1999; 84; 169–173.
8. Toll A, Salgado R, Yebenes M et al. MYC gene numerical aberrations in actinic keratosis and cutaneous squamous cell carcinoma. Br. J. Dermatol. 2009; 161; 1112–1118.
9. Blancato J, Singh B, Liu A, Liao DJ, Dickson RB. Correlation of amplification and overexpression of the c-myc oncogene in high-grade breast cancer: FISH, in situ hybridisation and immunohistochemical analyses. Br. J. Cancer 2004; 90; 1612–1619.
10. Kraehn GM, Utikal J, Udart M et al. Extra c-myc oncogene copies in high risk cutaneous malignant melanoma and melanoma metastases. Br. J. Cancer 2001; 84; 72–79.
11. Valentino C, Kendrick S, Johnson N et al. Colorimetric in situ hybridization identifies MYC gene signal clusters correlating with increased copy number, mRNA, and protein in diffuse large B-cell lymphoma. Am. J. Clin. Pathol. 2013; 139; 242–254.
12. Evan GI, Lewis GK, Ramsay G, Bishop JM. Isolation of monoclonal antibodies specific for human c-myc proto-oncogene product. Mol. Cell. Biol. 1985; 5; 3610–3616.
13. Hilpert K, Hansen G, Wessner H et al. Anti-c-myc antibody 9E10: epitope key positions and variability characterized using peptide spot synthesis on cellulose. Protein Eng. 2001; 14; 803–806.
14. Gurel B, Iwata T, Koh CM et al. Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis. Mod. Pathol. 2008; 21; 1156–1167.
15. Williams AR, Piris J, Wyllie AH. Immunohistochemical demonstration of altered intracellular localization of the C-Myc oncogene product in human colorectal neoplasms. J. Pathol. 1990; 160; 287–293.
16. Cattoretti G. MYC expression and distribution in normal mature lymphoid cells. J. Pathol. 2013; 229; 430–440.
17. Ben-David E, Bester AC, Shifman S, Kerem B. Transcriptional dynamics in colorectal carcinogenesis: new insights into the role of c-Myc and miR17 in benign to cancer transformation. Cancer Res. 2014; 74; 5532–5540.
18. Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012; 487; 330–337.
19. Quirke P, Risio M, Lambert R, von Karsa L, Vieth M, International Agency for Research on Cancer. European guidelines for quality assurance in colorectal cancer screening and diagnosis. First Edition—Quality assurance in pathology in colorectal cancer screening and diagnosis. Endoscopy 2012; 44(Suppl. 3); SE116–SE130.
20. Baker AM, Graham TA, Elia G, Wright NA, Rodriguez-Justo M. Characterization of LGR5 stem cells in colorectal adenomas and carcinomas. Sci. Rep. 2015; 5; 8654.
21. Kriegl L, Vieth M, Kirchner T, Menssen A. Up-regulation of c-MYC and SIRT1 expression correlates with malignant transformation in the serrated route to colorectal cancer. Oncotarget 2012; 3; 1182–1193.
22. Torlakovic EE, Gomez JD, Driman DK et al. Sessile serrated adenoma (SSA) vs. traditional serrated adenoma (TSA). Am. J. Surg. Pathol. 2008; 32; 21–29.
23. Rubio CA. Further studies on the arrest of cell proliferation in tumor cells at the invading front of colonic adenocarcinoma. J. Gastroenterol. Hepatol. 2007; 22; 1877–1881.
24. Smeland E, Godal T, Ruud E et al. The specific induction of myc protooncogene expression in normal human B cells is not a sufficient event for acquisition of competence to proliferate. Proc. Natl Acad. Sci. USA 1985; 82; 6255–6259.
25. Iritani BM, Eisenman RN. c-Myc enhances protein synthesis and cell size during B lymphocyte development. Proc. Natl Acad. Sci. USA 1999; 96; 13180–13185.
26. Ahuja P, Zhao P, Angelis E et al. Myc controls transcriptional regulation of cardiac metabolism and mitochondrial biogenesis in response to pathological stress in mice. J. Clin. Invest. 2010; 120; 1494–1505.
27. Spotts GD, Patel SV, Xiao Q, Hann SR. Identification of downstream-initiated c-Myc proteins which are dominant-negative inhibitors of transactivation by full-length c-Myc proteins. Mol. Cell. Biol. 1997; 17; 1459–1468.
28. Xiao Q, Claassen G, Shi J, Adachi S, Sedivy J, Hann SR. Transactivation-defective c-MycS retains the ability to regulate proliferation and apoptosis. Genes Dev. 1998; 12; 3803–3808.
29. Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial–mesenchymal transition. Nat. Rev. Mol. Cell Biol. 2014; 15; 178–196.
30. Cuchillo R, Michel J. Mechanisms of small-molecule binding to intrinsically disordered proteins. Biochem. Soc. Trans. 2012; 40; 1004–1008.
31. Dyson HJ, Wright PE. Intrinsically unstructured proteins and their functions. Nat. Rev. Mol. Cell Biol. 2005; 6; 197–208.
32. Collawn JF, Wallace CJ, Proudfoot AE, Paterson Y. Monoclonal antibodies as probes of conformational changes in protein-engineered cytochrome c. J. Biol. Chem. 1988; 263; 8625–8634.
33. Koide A, Abbatiello S, Rothgery L, Koide S. Probing protein conformational changes in living cells by using designer binding proteins: application to the estrogen receptor. Proc. Natl Acad. Sci. USA 2002; 99; 1253–1258.
34. Peter S, Bultinck J, Myant K et al. Tumor cell-specific inhibition of MYC function using small molecule inhibitors of the HUWE1 ubiquitin ligase. EMBO Mol. Med. 2014; 6; 1525–1541.